January 27, 2023
Sector changes, evolves and disintegrates as many wait for an algorithmic bromide
Pre-open Indications: 3 Negative Indications and 2 Positive Indication
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth! Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors!
Join me … in the NO spin zone.
The 8:00 a.m. edition
January 25, 2023
PGEN closed up (Tuesday) +$0.02 to $2.19 with a market response to the S-3 of -$0.60 or -27.625% to $1.59
Also granted the underwriters a 30-day option to purchase up to an additional $11.25 M of its common stock.
January 27, 2023
Big economic number’s drops and pops day as sector luckily moves to the upside
Pre-Open Indication: 2 Hits and 3 MISS
The Biostage (OTCQB: BSTG) Chronicles: four (4) sessions in a row with 2K shares traded each session, the pump (volume) and promote (share price) this week to keep the value up; after Monday’s -$0.09 and two (2) NO volume days. Shouldn’t the SEC be monitoring? Should U.S. investors trust any forthcoming offering?
I write this blog/newsletter to inform investors with facts and supporting numbers focused on what they need to hear that others won’t say or write about - truth!
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
January 25, 2023
PGEN closed up (Tuesday) +$0.02 to $2.19 with a market response to the S-3 of -$0.60 or -27.625% to $1.59 Also granted the underwriters a 30-day option to purchase up to an additional $11.25 M of its common stock.
January 24, 2023
Definitive agreement to sell approximately 2.1 million shares of its Series B Convertible Preferred Stock to affiliates of BVF Partners L.P. of $60 million in two tranches VSTM closed up +$0.02 to $0.61 with a negative -$0.01 or -1.66% aftermarket - so far and STILL de-listed from Nasdaq
January 18, 2023
BLUE priced at $6.00, the aftermarket is up +$0.12 or +2.07% BLUE also intends to grant the underwriters a 30-day option to purchase up to an additional 3,000,000 shares of its common stock to be sold in the offering.
© 2023 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.
